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Abstract
Although effective treatment regimens (surgical resection, drug treatment with dopamine agonists or somatostatin 
analogues, radiotherapy) have been established for the therapy of most pituitary tumours, a considerable 
proportion of affected patients cannot completely cured due to incomplete resection or drug resistance. Moreover, 
even if hormone levels have been normalized, patients with hormone-secreting tumours still show persistent 
pathophysiological alterations in metabolic, cardiovascular or neuropsychiatric parameters and have an impaired 
quality of life. In this review reasons for the discrepancy between biochemical cure and incomplete recovery from 
tumour-associated comorbidities are discussed and the clinical management is delineated exemplarily for patients 
with acromegaly and Cushing’s disease. In view of the development of additional treatment concepts for the treatment 
of pituitary adenomas we speculate about the relevance of RSUME as a potential target for the development of an 
anti-angiogenic therapy. Moreover, the role of BMP-4 which stimulates prolactinoma development through the Smad 
signalling cascade is described and its role as putative drug target for the treatment of prolactinomas is discussed. 
Regarding the well-known resistance of a part of somatotropinomas to somatostatin analogue treatment, recently 
identified mechanisms responsible for the drug resistance are summarized and ways to overcome them in future 
treatment concepts are presented. Concerning novel therapeutic options for patients with Cushing’s disease the 
impact of retinoic acid, which is currently tested in clinical studies, is shown, and the action and putative therapeutic 
impact of silibinin to resolve glucocorticoid resistance in these patients is critically discussed.
Correspondence 
should be addressed 







Prof. Dr med. Günter Stalla is currently Director of Medicover Neuroendocrinology, Munich 
with a clinical trial centre and Research Associate at the Medizinische Klinik und Poliklinik 
IVder Ludwigs-Maximilians-Universität, München. Dr Stalla has been honoured with awards 
such as the Schoeller-Junkmann-Prize from the DGE and the Rolf Gaillard Prize from the ENEA. 
Dr Stalla’s translational research interests include neuroendocrinology, pathogenesis and treatment 
of pituitary tumors, diagnosis and treatment of pituitary insufficiency, pharmacological targeting, 
neuroimmune-endocrinology, traumatic brain injury, epidemiology of endocrine diseases, 
metabolic abnormalities, obesity, sex development disorders and transsexualism.
Review























Pituitary tumours are mostly sporadic monoclonal 
neoplasias of the different cell types of the anterior pituitary 
(1). Whereas hormone-inactive pituitary adenomas cause 
pathophysiological problems (headache, visual field loss, 
pituitary insufficiency) due to the intracranial mass effects 
of the expanding tumour, hormone-active adenomas 
exhibit more complex pathophysiological disorders as 
a consequence of the excessive hormone production 
(2) (Fig. 1). For most pituitary tumour types, effective 
treatment regimens have been established including 
surgical removal, treatment with drugs such as different 
dopamine agonists (prolactinomas), the growth hormone 
receptor antagonist pegvisomant (somatotropinomas) 
and several somatostatin analogues (somatotropinomas, 
corticotropinomas), or radiotherapy (2, 3). However, 
complete resection of critically located or invasively 
growing adenomas is not possible and a considerable 
proportion of the tumours are resistant to established drug 
treatment regimens or alternate radiotherapy. In some 
cases, surgery or radiation-induced destruction of normal 
pituitary tissue will lead to partial pituitary insufficiency 
which then causes additional pathophysiological problems 
for the affected patients (4) (Fig. 1). Adenomas resistant to 
standard treatment options are at risk to develop a more 
aggressive tumour phenotype and in very rare cases will 
transform to a lethal pituitary carcinoma (1). Moreover, 
even if the patients with pituitary tumours have been 
biochemically cured they still show persistent alterations 
in neuropsychiatric or metabolic comorbidities and have 
an impaired quality of life (4). Thus, the development 
of additional treatment concepts still represents a major 
focus in pituitary tumour research. Using factor-specific or 
multifactorial (e.g. proteome or transcriptome analyses) 
approaches, multiple changes in the expression of 
miRNA, growth factors, cytokines, neuropeptides and/or 
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have been described in pituitary adenomas in comparison 
to the normal pituitary (5, 6, 7). Although it is not clear, 
whether these alterations play a causative role in pituitary 
tumorigenesis or are a consequence of the neoplastic 
transformation, they represent putative therapeutic 
targets to improve the treatment of the adenomas. In this 
review the discrepancy between biochemical and ‘real’ 
cure of patients with pituitary tumours is exemplarily 
discussed for patients with acromegaly and Cushing’s 
disease. Moreover, the putative role of different factors 
(Zac1, BMP4, retinoic acid, HSP90, RSUME) as targets 
of new treatment concepts, some of which are actually 
approved in clinical trials, are critically discussed.
Clinical management and outcome in 
Cushing’s disease
Cushing’s disease (CD), caused by an ACTH-secreting 
pituitary adenoma, is accounting for 70% of cases of 
endogenous Cushing’s syndrome (CS). The average 
incidence for CD ranges from 1.2 to 2.4 cases per million 
per year (8).
Clinical management
Transsphenoidal surgery (TSS) presents the treatment of 
choice for CD, as it typically leads to rapid and lasting 
remission of hypercortisolism while preserving the 
function of the pituitary gland and adrenal glands in most 
patients. Remission and recurrence rates vary dependent 
on tumour size, extension, adenoma visibility on MRI, 
and neurosurgical expertise (9). Patients with persistent 
or recurrent CD need to be considered for additional 
therapies such as repeat TSS, radiation therapy, medical 
therapy or bilateral adrenalectomy in order to minimize 
consequences of hypercortisolism.
Specialised CD care should not only focus on the early 
postoperative management, but also on the long-term 
follow-up. Recently, a structured short- and long-term 
management plan for CD patients in remission with focus 
on identifying cognitive impairments and psychiatric 
disorders, evaluating cardiovascular risk, following 
pituitary function and detecting possible CD recurrence 
has been proposed (10).
Somatic and neuropsychiatric comorbidities
CD is associated to increased morbidity and mortality, 
mostly due to cardiometabolic comorbidities such as 
arterial hypertension, glucose intolerance, diabetes 
mellitus, dyslipidemia, thromboembolic complications 
as well as a hypercoagulable state compared to sex- and 
age-matched subjects, CD patients present at diagnosis 
with higher BMI, waist-to-hip ratio, total, low-density 
lipoprotein cholesterol and total/high-density lipoprotein 
(HDL) ratio, glucose and insulin, as well as lower HDL 
cholesterol (11).
Treatment for hypercortisolism has been associated 
with a significant reduction in mortality and morbidity. 
However, even after long-term cure of the disease (mean 
time of hormonal cure, 11 ± 6 years), patients exhibit 
persistent accumulation of central fat, as in active 
hypercortisolemia leading to a persistent, unfavourable 
cardiometabolic risk profile. A recent meta-analysis 
confirmed that mortality remains increased even after 
initial biochemical cure, suggesting again that cure 
does not directly reverse the metabolic consequences 
of long-term overexposure to cortisol; hypopituitarism, 
including persistent adrenocortical insufficiency 
after surgery, may also contribute to the increased 
mortality risk (12).
Clinical presentation of CD reflects chronic cortisol 
excess and comprises in more than 70% of patients a broad 
spectrum of psychological or psychiatric manifestations 
with (major) depression being the most frequent 
disturbance. Depression may ultimately even lead to 
suicide, anxiety, personality changes, mania and psychosis 
(13). Further neuropsychological disturbances frequently 
include changes in appetite, insomnia and irritability. 
Psychic disturbances do not necessarily correlate with 
the degree of hypercortisolism and can range from mild 
to severe. Some kind of psychiatric disturbance often 
remains despite biochemical remission of CD.
As far as personality is concerned, CS patients display 
significantly higher scores in anxiety, depression and 
psychotic symptoms compared to healthy controls. In our 
own series, CD patients reported significantly less novelty-
seeking behaviour, presented with more anticipatory 
worries and pessimism, higher fear of uncertainty, shyness 
with strangers and appeared to be less extraverted, more 
neurotic and socially desirable, compared to mentally 
healthy controls (14).
Several studies point out the impact of chronic 
exposure to elevated glucocorticoid levels with deficits 
in cognitive function, concentration and short-term 
memory as well as brain morphology changes (brain 
atrophy and low hippocampal volume). Brain volume 
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It is known that patients with pituitary adenomas 
frequently suffer from pain syndromes for example, 
headache due to structural and functional properties of 
the tumour. In a cross-sectional study, we assessed 278 
patients with pituitary disease including 45 CD patients. 
We recorded a high prevalence of bodily pain (65%) and 
headache (64%); adrenocorticotropic adenomas were 
most frequently associated with pain (76%). Headache 
was equally frequent in patients with macro- and 
microadenomas (P = 0.266), while the majority of patients 
suffered from nociceptive pain (80%) (16).
Quality of Life (QoL)
Impaired quality of life (QoL) in active CD is a stable 
and consistent finding in many different studies having 
implications for the long-term management of the 
disease. The significant impact of chronic exposure 
to hypercortisolism on patient’s health and health-
related quality of life (HRQoL) has been demonstrated 
with generic questionnaires (17). The presence of pain 
and pain-related disability correlates significantly with 
impaired QoL in CD (16). All HRQoL parameters improve 
after treatment with TSS, however, even after long-term 
remission of CS, impaired QoL persists as a remaining 
effect of long-standing hypercortisolism, especially in the 
presence of hypopituitarism (18).
Clinical management and outcome 
in acromegaly
Not only the clinical management of Cushing’s disease 
represent a major challenge due to a high load of 
comorbidities. Also in patients with other pituitary diseases 
such as acromegaly, the long-lasting hormonal excess (in 
this case GH and IGF-1) leads to severe chronic conditions 
such as organomegaly, facial disfigurement, arthropathy, 
diabetes mellitus, hypertension, and neurological and 
psychiatric complications that reduce patients’ quality of 
life (QoL). Since the complex clinical picture is difficult 
to ascribe to the correct underlying disease, it often takes 
up to 10 years of GH/IGF-1 excess until the appropriate 
diagnostic work-up and treatment is initiated.
Clinical management
The latest consensus on clinical management of 
acromegaly has been published after the Acromegaly 
Consensus Conference in April 2017 (3). In brief, clinical 
management in acromegaly aims at normalizing GH 
and/or IGF-1 levels to reduce comorbidities, symptoms 
and mortality rates. After transsphenoidal surgery more 
than 30% of patients remain biochemically uncontrolled 
(or cannot be operated in the first place) and are treated 
with medical therapies (including dopamine agonists, 
somatostatin analogues and GH receptor antagonists). 
For those who do not achieve normal IGF-1 levels after 
second-line therapy, stereotactic radiosurgery remains 
an alternative.
A multidisciplinary team ideally treating the patient 
at a pituitary tumour centre of excellence should not 
only aim at normalizing hormonal levels, but should 
also diagnose and manage acromegaly-associated 
comorbidities (3).
Somatic and neuropsychiatric comorbidities
Among the extensive list of symptoms and diseases, 
metabolic, cardiovascular and respiratory comorbidities 
seem to be the major causes of elevated mortality rates in 
acromegaly and should be treated aggressively (3).
To monitor the management of the most severe 
comorbidities and symptoms, evaluated instruments 
such as the SAGIT (Signs and symptoms, Associated 
comorbidities, GH levels, IGF1 levels and Tumour profile), 
the ACRODAT (Acromegaly Disease Activity Tool) as 
well as in selected cases the acromegaly-specific patient 
questionnaire AcroQoL that measures health-related QoL 
can be considered (3).
Besides the most prevalent metabolic and 
cardiovascular morbidities, a recent systematic review on 
neuropsychiatric symptoms underlines once more the 
clinical relevance of psychiatric morbidities in pituitary 
disease that are often underdiagnosed and undertreated 
(19). In acromegaly, neurocognitive alterations were 
detected in 2–33% of study patients while psychiatric 
disorders occurred in up to 63% of patients (with 
depression being the most common).
Although normalized IGF-1 levels achieved by 
treatment usually improve somatic comorbidities, 
they may fail to restore mental health problems and 
normalize patient-related QoL (20, 21). This lack of 
reactivity to treatment might be due to persistent 
neuronal changes following chronic GH-IGF-1 excess 
which could be reflected by grey matter and white 
matter volume changes, decreased oscillation activity 
in EEG bands of the prefrontal and middle temporal 
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Another reason for reduced mood and QoL in 
acromegalic patients might be persisting pain syndromes. 
In the already mentioned study, we assessed 278 patients 
with pituitary diseases including 81 patients with 
acromegaly. Patients reported a high prevalence of bodily 
pain (65%) and headache (64%) correlating significantly 
with depression and impaired QoL (16).
Quality of life
Besides the reduction of mortality and morbidity, the 
World Health Organization recognizes the improvement 
of QoL as the third major treatment goal in chronic 
diseases. However, QoL often remains reduced relative 
to the normal population despite long-term biochemical 
cure in acromegaly.
In a primary study and in a systematic review 
including 51 studies, we analysed the contribution of 
various determinants of QoL in several disease stages 
of acromegaly (24, 25). There was incongruent data 
to support that biochemical control, or treatment of 
acromegaly in general, is associated with improved QoL. 
However, in cross-sectional studies and analyses, factors 
such as depression and obesity were associated with 
reduced QoL. This might further support the strategy in 
which acromegaly patients should be treated with the 
aim not only to reach biochemical control, but also to 
consider psychosocial or weight-lowering interventions 
as additional and independent part of the management.
Expression and function of RSUME in 
pituitary tumours
RSUME (RWD-domain-containing sumoylation enhancer, 
also known as RWDD3) was cloned from the pituitary 
lacto-somatotroph tumour cell GH3 overexpressing the 
IL-6 cytokine transducer gp130 (26). Five of the seven 
human RSUME mRNA splice variants that have been 
described so far, code for different RSUME isoforms and 
two correspond to non-coding RNAs that suffer nonsense-
mediated RNA decay. The five isoforms have an RWD 
domain in the N-terminus of the protein (26, 27). RSUME 
was originally found to be highly expressed in various 
tissues such as pituitary, cerebellum, heart, kidney, 
pancreas and adrenal gland. RSUME is upregulated by 
cellular stress such as hypoxia and heat shock (26, 27).
The pituitary tumour cell from which RSUME was 
cloned showed increased tumorigenic and angiogenic 
potential when experimentally injected into nude mice 
with respect to a control GH3 stable cell line. Beside 
pituitary adenomas, RSUME was found to be expressed in 
other types of tumours with high angiogenic potential, 
among them gliomas (28) and pancreatic neuroendocrine 
tumours (29). Particularly, RSUME is expressed in tissues 
prone to tumour development in Von Hippel Lindau 
(VHL) syndrome and is upregulated in several tumours 
related to this disease (27, 30). Accordingly, it has been 
associated with decreased survival in a group of renal cell 
carcinoma patients (30).
Under hypoxic conditions, RSUME expression is 
upregulated and increases HIF-1and 2α protein levels 
(26, 30). Consequently, RSUME induces vascular 
endothelial growth factor (VEGF) mRNA and protein 
expression during hypoxia (26, 31) (Fig. 2). In line with 
this, downregulation of endogenous RSUME by shRNA, 
produces the inhibition of HIF-1α stabilization during 
hypoxia (26). Interestingly, RSUME sumoylates and has 
a protein-protein interaction with pVHL in normoxia 
and negatively regulates the assembly of the ECV (the 
VHL-E3 ligase complex that produces the degradation 
of HIF, composed of Cullin2, Rbx1, Elongin B, Elongin 
C), thus inhibiting HIF-1 and 2α ubiquitination and 
degradation. Through this mechanism RSUME regulates 
the loss of function of type 2 VHL mutants (27, 30).
In line with the above mentioned regulation, RSUME 
expression is increased by hypoxia in pituitary tumours 
(31). The anterior pituitary is one of the most densely 
vascularized organs due to the flux of information among 
the hypothalamus, pituitary and its target organs, which 
is mediated mainly through hormones transported within 
the bloodstream.
Hypoxia triggers neovascularization, that is, the 
formation of new vessels and improves oxygen delivery 
under persistent hypoxic conditions into the developing 
tumour through HIF, which induces the expression 
of different angiogenic factors such as VEGF, bFGF 
and PDGF. In particular, VEGF, which also stimulates 
pituitary tumour cell growth, is thought to play a key 
role in pituitary tumour progression. RSUME has a 
critical role in this process. As mentioned, RSUME was 
shown to stabilize HIF-1α during hypoxia, thus inducing 
expression of angiogenic factors like VEGF (26). Shan 
et  al. demonstrated that RSUME mRNA is upregulated 
in pituitary adenomas and significantly correlated with 
HIF-1α mRNA levels (31). The relation between RSUME, 
HIF and VEGF was further proved in pituitary adenomas 
(32). Hypoxia enhanced RSUME and HIF-1α expression, 
induced its translocation to the nuclei and stimulated 
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human pituitary adenoma cell cultures (31). In addition, 
when RSUME expression was specifically downregulated, 
VEGF expression was strongly reduced (31). By supporting 
pituitary tumour neovascularization, RSUME represents 
a new putative target for the development of new anti-
angiogenic therapeutic treatment for pituitary tumours.
Originally isolated from the rat pituitary tumour cell 
line GH4, pituitary transforming tumour gene (PTTG) has 
been shown to be elevated and involved in the growth 
of pituitary adenomas. No mutations or epigenetic 
modifications that explain high PTTG expression and 
action as oncogene have been found. Recently, it has 
been described that RSUME increases PTTG protein half-
life and protein stabilization in pituitary tumour cell 
lines and enhances PTTG transcription factor and securin 
activities. RSUME knockdown reverts its actions on PTTG 
abundance and transcriptional activity and reduces PTTG 
tumorigenic potential in pituitary cell lines injected in 
nude mice, accounting for PTTG pathogenic action (33).
In summary, RSUME regulates important pathogenic 
(i.e. angiogenesis/VEGF and oncogene PTTG) factors and 
processes that trigger pituitary adenoma development.
Role of BMP-4 in prolactinomas
There has been considerable progress in the understanding 
of the pathogenic mechanism of prolactinomas in the 
last decades. For example, oestrogens cause lactotroph 
hyperplasia and stimulate the expression of vascular 
endothelial growth factor (34), pituitary tumour-
transforming gene (35) and galanin (36). On the 
other hand, dopamine plays the major role in keeping 
lactotroph cells suppressed. The dopamine receptor 
agonist cabergoline is widely used to treat patients 
with prolactinomas and the dopamine receptor DRD2-
knockout mouse spontaneously develops lactotroph 
hyperplasia and prolactinomas (37). Comparing 
DRD2−/− tumours versus the normal pituitary by mRNA 
differential display, we found that the BMP antagonist 
noggin is downregulated and BMP-4 is overexpressed 
in prolactinomas (38). BMP-4 is a member of the TGF-
beta family of cytokines that plays an important role 
in cell differentiation and proliferation. The differential 
expression of BMP-4 and noggin in prolactinomas 
was then confirmed in prolactinoma models, such as 
oestradiol-treated rats, and also in biopsy samples from 
human prolactinomas. Through the Smad pathway, 
BMP-4 stimulates the expression of the cell cycle 
regulator c-Myc, resulting in increased cell proliferation. 
GH3 cells stably transfected with expression vectors that 
inhibit BMP-4 showed reduced tumourigenicity in nude 
mice, which supports a stimulatory role for BMP-4 in 
prolactinoma development in vivo (38).
The mechanisms of BMP-4 that impact hormone 
secretion and gene transcription in the lacto-somatotroph 
cell line GH3 are known in considerable detail (39) (Fig. 3). 
We initially demonstrated a crosstalk between BMP-4 and 
oestrogen in prolactinoma cells which results in a strong 
additive stimulatory effect at low concentrations on 
c-Myc expression and cell proliferation (38). This crosstalk 
occurs also at the level of the transcriptional activity of 
the prolactin promoter, resulting in an increased prolactin 
secretion. BMP-4 inhibits the transcriptional activity 
of oestrogen receptor (ER) at low doses of oestradiol. In 
contrast, oestrogens stimulate the transcriptional activity 
of Smad 1/5/8, which is a specific mediator of the BMP 
pathway. We found that the prolactin promoter contains 
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Figure 2
Effect of RSUME in pituitary tumour cells. Under hypoxic 
conditions, RSUME supports the stabilisation of HIF-1α, and 
thus, enhances the transcriptional activity of HIF-1 to stimulate 
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to the BMP-4 and oestrogen crosstalk. Mutations in the 
oestrogen response element in the prolactin promoter 
alone are not enough to inhibit the crosstalk but a Smad1 
dominant negative abolishes it. Using serial deletions of 
the prolactin promoter and CHIP analysis, we were able 
to identify a sequence responsive to BMP-4 and Smad1. 
This new response element is located upstream to the 
transcriptional start site of the prolactin promoter. Smad-4 
forms a functional complex with Smad 1/5/8 after BMP-4 
stimulation and binds to this DNA sequence, which 
was demonstrated by chromatin immunoprecipitation, 
specific mutation, and gel shift assay. The reciprocal 
regulation mechanism between both pathways, which 
involves BMP-4, Smads, and ER, contributes to the specific 
control of prolactin synthesis in prolactinoma cells (40). 
In addition, both pathways also regulate the mechanisms 
of cell proliferation that result in the development and 
progression of prolactinomas. Interestingly, BMP-4 has 
opposite actions in corticotroph cells as described in 
detail in the retinoic acid section.
Delineating somatostatin receptor 
signalling cascades to combat somatostatin 
analogue resistance in pituitary tumours
With the exception of lactrotroph tumours that are 
successfully managed with dopamine receptor type 2 
agonists, surgery remains the mainstay treatment (2). 
First-generation somatostatin analogues (SSAs) that 
target mainly somatostatin receptor 2 (SSTR2) are used 
for the treatment of acromegaly. However, in 40–60% of 
patients the SSA treatment fails to achieve biochemical 
control and/or tumour shrinkage (41). Understanding the 
mechanisms driving pituitary tumorigenesis may enable 
us to find ways to combat treatment resistance.
The pathogenesis of pituitary tumours is subject of 
intense ongoing investigation. Here we will describe 
our studies on ZAC1, a putative mediator of SSA action 
in pituitary cells. ZAC1 (Zn finger protein regulating 
apoptosis and cell cycle arrest, gene name: pleiomorphic 
adenoma gene-like 1, PLAGL1) is a tumour suppressor 
gene cloned from a corticotroph tumour cell line (42). 
ZAC1 is downregulated in the majority of pituitary 
adenomas compared to the normal anterior pituitary, but 
not in somatotroph tumours from patients that have been 
treated with SSA preoperatively (43). Using a rodent lacto-
somatotroph cell line, we observed that the SSTR2 ligand 
octreotide upregulates ZAC1 expression and knocking 
down endogenous ZAC1 abolishes its anti-proliferative 
action (44). A follow-up immunohistochemical analysis in 
human somatotroph tumours confirmed the importance 
of ZAC1 as SSA mediator demonstrating a significant 
correlation between ZAC1 immunoreactivity and patient 
response to treatment in terms of biochemical control and 
tumour shrinkage (45). An independent study confirmed 
that octreotide upregulates ZAC1, which interacts with 
the aryl hydrocarbon receptor-interacting protein (AIP) 
and may be responsible for the SSA resistance seen in 
acromegaly patients bearing AIP mutations (46).
Having ZAC1 as a readout endpoint we embarked in 
delineating pituitary-specific SSTR2 signalling, that until 
then was studied mainly in heterologous cell systems 
overexpressing the receptor (41). We discovered that SSA 
induces ZAC1 gene expression by suppressing the PI3K/
AKT signalling (44). The PI3K/AKT survival pathway is 
implicated in several aspects of tumour biology including 
chemotherapy resistance, indicating that its blockage 
could sensitize pituitary tumour cells to SSA. Indeed 
overexpressing AKT in our somatotroph tumour cell line 
abolished the anti-proliferative action of octreotide (47). 




















Action of BMP-4 in prolactinomas. After binding to its 
receptors on the surface of lactotroph tumour cells, BMP-4 
induces the phosphorylation of Smad 1 which then forms a 
complex with Smad 4. After translocation to the nucleus and 
binding to corresponding specific effector sites the Smad 1/4 
complex induces proliferation and prolactin production in 
lactotroph tumour cells. These processes are enhanced 
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of human non-functioning pituitary tumours that display 
high AKT phosphorylation and generally do not respond 
to SSA treatment despite the presence of SSTRs (48). PI3K 
pathway inhibition downstream at mTOR level with 
rapamycin sensitized the resistant tumour to octreotide 
and improved the response of the few responders as 
determined by suppression of thymidine incorporation 
(3H-TdR; surrogate marker of DNA synthesis and cell 
viability) (47).
Intriguingly, the majority of these NFPA tumours 
did not respond to the single rapamycin system either, 
suggesting that the SSA is in turn sensitizing the tumour 
cells to rapamycin. In fact, the same issue of Cancer 
Research that published our octreotide signalling data, 
published a ground-breaking study demonstrating in 
breast cancer tumours that resistance to the rapamycin 
analogue everolimus is induced by the inhibitor itself, 
since it removes a negative feedback loop to AKT that 
physiologically occurs downstream of mTOR (49). Using 
a pituitary tumour cell line that does not respond to 
rapamycin we showed that the upstream inhibitory 
action of octreotide on the PI3K/AKT pathway renders 
the rapamycin-induced loss of the negative feedback loop 
obsolete allowing rapamycin to induce cell cycle arrest (47). 
A randomized, placebo-controlled, phase 3 study reported 
improved progression-free survival with the combined 
everolimus-octreotide-LAR compared to single octreotide-
LAR treatment (50). Several clinical trials on the combined 
treatment with everolimus and SSA have been registered, 
their majority testing efficacy on advanced neuroendocrine 
tumours. Despite the initial favourable outcome, latest 
reports on final overall survival failed to show better 
efficacy of the combined treatment versus octreotide-
LAR (neither did of single everolimus treatment versus 
placebo) (51). Heterogeneity in the patient population 
combined with the relatively low patient numbers and 
severe side effects considering the slow-growing tumours 
in patients with advanced NET and carcinoid syndrome 
may account for this discouraging outcome. This setback 
may give the opportunity to look more closely into other 
aspects of tumour biology such as tumour heterogeneity 
and microenvironment and how they influence treatment 
response from in vitro models to patients.
Role of retinoic acid in the treatment of 
Cushing’s disease
Retinoic acid (RA), a derivate of vitamin A, inhibits POMC 
transcription and its stimulation by CRH in the pituitary 
ACTH-secreting tumour cell line AtT-20, which is an 
experimental cellular model of pituitary corticotroph 
adenomas. This effect was confirmed in primary cultures 
of human corticotropinomas whereas RA had no effect on 
non-tumour pituitary cells (52).
In normal pituitary cells, the expression of COUP-
TFI might explain why RA does not affect normal ACTH 
secretion. While normal ACTH-secreting cells express high 
levels of COUP-TFI, corticotroph tumour cells do not (52). 
A study in human corticotropinoma samples (29 out of 
34) has shown that most of these tumours do not express 
COUP-TFI (53). In fact, when tumour cells responding to 
RA are transfected with a COUP-TFI expression vector, the 
response to RA is abolished (52). This difference between 
normal and tumour cells makes COUP-TFI expression a 
promising biomarker of a possible response to RA.
RA works in corticotroph cells through a complex 
mechanism of action, involving hormone regulation, 
cell proliferation, differentiation, and chromatin 
remodelling (Fig. 4). In corticotroph tumour cells, RA 
induces the expression of the dopamine receptor DRD2 
through a process of cell differentiation (54). In addition 
to the inhibition of hormone secretion, RA inhibits the 
proliferation of corticotroph and corticosterone-secreting 
tumour cell lines. These anti-proliferative effects involve 
transcription factors such as AP-1 and Nur77/Nurr1 
(52). In AtT-20 pituitary tumour cells RA also induces 
the expression of the BMP-4, a cytokine that mediates 
the anti-proliferative effects of RA (55). Similarly, BMP-4 
has been shown to be involved in the inhibitory action 
of somatostatin analogues on corticotrophs (56). In 
GH3 and AtT-20 cells, RA-induced expression of BMP-4 
involves chromatin remodelling (57). These interactions 
between RA and BMP-4 in corticotroph cells might 
provide further insight into the therapeutic potential of 
RA in corticotroph tumours.
In nude mice bearing AtT-20 xenografts, an in vivo 
model of corticotroph tumours, RA treatment reduces 
tumour growth and reverses the typical alterations 
resulting from high levels of glucocorticoids. RA decreases 
plasma ACTH and cortisol levels, which results in a 
reduction of adrenal hyperplasia and skin atrophy in 
these animals (52).
A 6-to-12-month RA treatment regimen in dogs with 
spontaneous Cushing’s disease not only normalized 
hormonal levels but prevented corticotroph adenomas 
from recurring. A dose of 2 mg/kg body weight/day of RA 
results proved to be efficacious and safe, without signs 
of hepatotoxicity (58). In addition to the reduction of 
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ACTH and α-MSH. These hormonal changes lead to the 
normalization of the oestrous cycle (58). After a period 
of 6 months of treatment, RA reduced the corticotroph 
adenoma size, improved clinical signs such as food intake, 
skin appearance and hair recovery and also strongly 
prolonged survival (58).
To date, two prospective clinical studies in human 
patients with Cushing’s disease have reported therapeutic 
effects of RA. RA treatment for a period of 6–12 months 
normalized ACTH and cortisol levels in many of the 
treated patients. An initial study of seven patients with 
Cushing disease (CD) showed that RA administration in 
doses of 10–80 mg/day reduced significantly UFC levels 
in five patients and three of them reached normalization 
(59). Another prospective study of 16 patients with 
persistent or recurrent CD, in which isotretinoin was 
given orally in doses ranging from 20 to 80 mg/day for 
6–12 months, a response was observed with an initial 
normalization of the UFC and salivary cortisol in six 
patients (37.5%). Subsequently, two patients became 
resistant to the treatment or relapsed. In comparison with 
non-responders patients, the responding patients had 
significantly lower mean age and lower mean basal levels 
of UFC, nocturnal salivary cortisol and ACTH. Therefore, 
the authors of this study concluded that RA might be more 
beneficial in patients with mild hypercortisolism (60).
Role of HSP90 in Cushing’s disease and 
potential treatment with silibinin
ACTH biosynthesis and secretion are under the 
negative feedback control of glucocorticoids in normal 
corticotroph cells. This mechanism is part of the normal 
regulation of the response to stress and brings back the 
hypothalamus-pituitary-adrenal axis to a basal state. In 
contrast, corticotroph tumour cells in Cushing’s disease 
produce excessive amounts of ACTH despite the high 
levels of circulating glucocorticoids in these patients. 
This and the altered response to challenge tests with 
dexamethasone indicate that the negative glucocorticoid 
feedback mechanism is impaired in these tumour cells 
(8). Inactivating mutations of the glucocorticoid receptor 
(GR) encoded by the nuclear receptor subfamily 3 group 
C member 1 (NR3C1) gene are rare and have not been 
found in Cushing’s disease in significant numbers. 
However, other mechanisms that control the activity of 
the glucocorticoid receptor could explain glucocorticoid 
resistance in these tumors (61).
In this regard, we discovered a novel biochemical 
mechanism involving the targeting of Heat Shock Protein 
90 (HSP90) (62). HSP90 is highly abundant in basal 
conditions and its gene expression is transcriptionally 
induced in response to cellular stress. HSP90 acts as a 
chaperone that promotes protein folding of hundreds of 
proteins, many of them involved in disease and cancer 
progression (63). Among these, are reported kinases that 
regulate cell cycle and many nuclear receptors, including 
the glucocorticoid receptor (GR). HSP90 directly interacts 
with GR ligand-binding domain (LBD), activating it for 
ligand binding and translocation into the nucleus (64). 
Therefore, HSP90 plays a central role in the response to 
glucocorticoids (62).
Depending on its expression level, HSP90 can also 
impair some of the steps that are necessary for GR function. 
After becoming fully mature, GR needs to be released from 
HSP90 (64). However, when HSP90 is overexpressed in 
corticotroph tumour cells, GR is retained in a cytoplasmic 
complex, leading to partial glucocorticoid resistance (62). 
In addition, we did not observe HSP90 overexpression 
in the normal anterior pituitary therefore our findings 
might explain the impaired response to glucocorticoids in 
patients with Cushing’s disease (62).
c-fos GR 
ACTH Glucocorticoids 
POMC AP-1 GRE NurRE NBRE 
Nur Nur 
+ + + - 
RAR RA 
Figure 4
Effect of retinoic acid (RA) in corticotropinomas. The activated 
RA receptor (RAR) inhibits the transcriptional activity of 
POMC-stimulating Nur77/Nurr1 and AP-1 transcription factors, 
and thus, suppresses the excessive ACTH production by 
corticotroph tumour cells. As these transcription factors also 
regulate the proliferation of corticotroph tumour cells, RA is 
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The general structure of HSP90 consists in a 
homodimer, composed by a highly conserved amino-
terminal domain (NTD) connected to a middle domain 
(MD) and followed by a carboxy-terminal domain (CTD) 
(64). NTD and CTD are the key players for the chaperone 
activity of HSP90 and the principal targets of specific 
inhibitors. In particular, the C-terminal domain is 
responsible for the final maturation and release of GR from 
the chaperone complex. C-terminal inhibitors of HSP90 
such as novobiocin and the herbal compound silibinin 
are able to increase the rate of release of mature GR from 
HSP90 in corticotroph tumour cells, thereby enhancing 
its transcriptional activity and overcoming glucocorticoid 
resistance by suppressing proopiomelanocortin (POMC) 
transcription (62) (Fig. 5). In this way, C-terminal 
HSP90 inhibitors might be able to compensate HSP90 
overexpression and restore the response to glucocorticoids 
to normal levels. In fact, silibinin administration was 
able to reverse glucocorticoid resistance in a corticotroph 
tumour allograft mouse model, leading to a significant 
reduction in the typical symptoms of the disease. These 
results in an animal model suggest that silibinin could 
be potentially efficacious for the treatment of Cushing’s 
disease (62, 65). Silibinin is already in clinical use for 
other indications and has an excellent safety record, 
which might facilitate the translation of these results into 
the clinic for patients with Cushing’s disease (66). Clinical 
studies with a special formulation of silibinin that delivers 
high levels of the substance into the circulation are now 
being planned and will soon be launched.
More recently, we showed that HSF1, the transcription 
factor that controls HSP90 transcription, is also highly 
expressed and active in Cushing tumours in comparison 
to the normal pituitary (67). The HSF1 inhibitor KRIBB11 
inhibited POMC transcription and ACTH synthesis in the 
AtT-20 cell line and in primary cultures from Cushing 
disease patients. As expected, this inhibitory action 
was mediated by increased GR and suppressed Nur77/
Nurr1 and AP-1 transcriptional activities (67). Therefore, 
HSF1 could be yet another potential drug target for the 
pharmacological treatment of Cushing’s disease.
Conclusions
Patients with hormone-active pituitary adenomas still 
suffer from hormone-excess-associated comorbidities 
even after the pituitary tumour has been successfully 
removed and the hormone levels have been normalized. 
Thus, biochemically cured patients still need a careful 
postoperative clinical management until they have 
achieved maximum recovery from tumour-associated 
health problems such as cardiovascular, metabolic or 
neuropsychiatric disorders.
For those patients, whose tumours cannot be 
completely removed and/or who are resistant to 
established drug treatments, alternative therapeutic 
options have been shown and discussed in this review. 
Whereas RSUME and BMP-4 actually remain putative 
targets waiting for the development of corresponding 
specific drugs, for other targets clinical trials have already 
been performed or are under investigation. Based on 
decoding the interaction of SSTR2, Zac1 and the PI3K/
AKT/mTOR pathway an improvement of the inhibitory 











Silibinin-induced recovery of glucocorticoid inhibitory action 
on ACTH in corticotropinomas. In corticotroph tumour cells, 
the overexpression of HSP90 leads to a decline of mature 
glucocorticoid receptor (GR) production and thus to 
glucocorticoid resistance. Treatment with silibinin, a 
C-terminal inhibitor of HSP90, leads to an enhanced 
production of GR and thus the recovery of glucocorticoid 
response. This is shown in the lower panel, in which the 
combined treatment of silibinin with the synthetic 
glucocorticoid dexamethasone (Dex) restores the 
responsiveness of corticotroph tumour cells to the ACTH 
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was achieved in some patients. RA had not only shown 
a good control of Cushing’s disease in vivo in dogs but 
also in clinical trials with human patients with Cushing’s 
disease. Based on elucidating the role of HSP90 as 
regulator of glucocorticoid receptor action, a clinical trial 
has currently been launched that will prove the efficacy of 
the HSP90 inhibitor silibinin on restoring glucocorticoid 
response in corticotroph tumours. Thus for patients with 
distinct types of pituitary tumours some new treatment 
options will soon be available.
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